Friday, February 26, 2010

Carolina Innovations Seminar - NC BioStart

Thursday, March 4, 2010 5:30-6:30pm

014 Sitterson Hall UNC-Chapel Hill

NC BioStart – Accelerating Technology Development at UNC Chapel Hill and Beyond

Speakers: Dr. Richard Boucher – Executive Director of NC BioStart & NC BioStart Entrepreneurs in Residence, Drs. Perry Genova, Joel Shaffer, and Tom Mercolino

UNC’s new NC BioStart program was established to increase the commercialization of intellectual property developed by our public universities in North Carolina, beginning in the first year at UNC and eventually including all UNC system schools. The program was started by the School of Medicine to meet the goals of its Clinical Translational Science Award, in partnership with the Office of Technology Development and the Kenan-Flagler Business School.

Dr. Richard Boucher, Executive Director of NC BioStart, Director of the UNC Cystic Fibrosis Center, and UNC entrepreneur, will be discussing the goals of the program and the resources that will be available through NC BioStart to our faculty, staff, and students which include a range of services from connecting faculty with industry experts to assisting with writing of business plans. Faculty can also be matched with an Entrepreneur in Residence (ER) to receive further consultation to explore their ideas. ERs Drs. Genova, Shaffer, and Mercolino (who have more than 75 years combined industry product development experience) will also discuss some of the exciting work that is currently ongoing at UNC through this program.

For more information on NC BioStart please visit their website at: http://tracs.unc.edu/index.php?option=com_content&view=article&id=448&Itemid=427


For more detailed information please visit - http://research.unc.edu/otd/carolina_innovations_seminar.php

Thursday, February 25, 2010

NC Biomedical Innovation Network Symposium RESCHEDULE

The North Carolina Biomedical Innovation Network, due to the greater-than-anticipated response to tomorrow's symposium, has decided to reschedule the program to be held at a later date in a larger local venue. This will enable everyone to attend the symposium who has expressed interest in it and will also lead to a more interactive program. Additionally, they are going to evaluate conducting an industry-wide symposium at a major scientific conference that will further showcase the extensive preclinical resources in North Carolina.

Monday, February 15, 2010

Registration information for the NC Biomedical Innovation Network Symposium

Registration for the N.C. Biomedical Innovation Network Symposium is open until Feb. 17 (seating is limited): http://bit.ly/bnAnae (PDF)

N.C. Biomedical Innovation Network Launches With February 26 Symposium

Thursday, February 11, 2010

FDA Unveils Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging

Initiative to focus on 3 types of procedures with high radiation doses

SILVER SPRING, Md., Feb. 9 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced an initiative to reduce unnecessary radiation exposure from three types of medical imaging procedures: computed tomography (CT), nuclear medicine studies, and fluoroscopy. These procedures are the greatest contributors to total radiation exposure within the U.S. population and use much higher radiation doses than other radiographic procedures, such as standard X-rays, dental X-rays, and mammography.

CT, nuclear medicine, and fluoroscopic imaging have led to early diagnosis of disease, improved treatment planning, and image-guided therapies that help save lives every day. The FDA continues to support a strong dialogue between patients and physicians over the medical necessity and risk associated with these types of imaging studies.

However, like all medical procedures, CT, nuclear medicine, and fluoroscopy pose risks. These types of imaging exams expose patients to ionizing radiation, a type of radiation that can increase a person's lifetime cancer risk. Accidental exposure to very high amounts of radiation also can cause injuries, such as skin burns, hair loss and cataracts. Health care decisions made by patients and their physicians should include discussions of the medical need and associated risks for each procedure.

"The amount of radiation Americans are exposed to from medical imaging has dramatically increased over the past 20 years," said Jeffrey Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. "The goal of FDA's initiative is to support the benefits associated with medical imaging while minimizing the risks."

While there is some disagreement over the extent of the cancer risk associated with exposure to radiation from medical imaging, there is broad agreement that steps can and should be taken to reduce unnecessary radiation exposure.

For example, the radiation dose associated with a CT abdomen scan is the same as the dose from approximately 400 chest X-rays. In comparison, a dental X-ray calls for approximately one-half the radiation dose of a chest X-ray. Both diagnostics serve important, sometimes critical, public health needs.

Through the FDA's regulatory oversight of medical imaging devices, such as CT scanners, and through collaboration with other federal agencies and health care professional groups, the FDA is advocating the adoption of two principles of radiation protection: appropriate justification of the radiation procedure and optimization of the radiation dose used during each procedure.

"Working together," said Shuren, "the FDA and other organizations hope to help patients get the right imaging exam, at the right time, with the right radiation dose."

The three-pronged initiative the FDA is announcing will promote the safe use of medical imaging devices, support informed clinical decision-making, and increase patient awareness of their own exposure.

The FDA intends to issue targeted requirements for manufacturers of CT and fluoroscopic devices to incorporate important safeguards into the design of their machines to develop safer technologies and to provide appropriate training to support safe use by practitioners. The agency intends to hold a public meeting on March 30-31, 2010, to solicit input on what requirements to establish.

Examples could include a requirement that these devices display, record, and report equipment settings and radiation dose, an alert for users when the dose exceeds a diagnostic reference level (the optimal dose for most patients), training for users, and a requirement that devices be able to capture and transmit radiation dose information to a patient's electronic medical record and to national dose registries.

In addition, the FDA and the Centers for Medicare and Medicaid Services are collaborating to incorporate key quality assurance practices into the mandatory accreditation and conditions of participation survey processes for imaging facilities and hospitals. These quality assurance practices will improve the quality of oversight and promote the safe use of advanced imaging technologies in those facilities.

The FDA recommends that health care professional organizations continue to develop, in collaboration with the agency, diagnostic radiation reference levels for medical imaging procedures, and increase efforts to develop one or more national registries for radiation doses.

A dose registry would pool data from many imaging facilities nationwide, capturing dose information from a variety of imaging studies. This registry will help define diagnostic reference levels where they do not yet exist, validate levels that do exist, and provide benchmarks for health care facilities to use in individual imaging studies.

In a bid to empower patients and increase awareness, the FDA is collaborating with other organizations to develop and disseminate a patient medical imaging history card. This tool, which will be available on the FDA's Web site, will allow patients to track their own medical imaging history and share it with their physicians, especially when it may not be included in their medical records.

FDA Web site on Radiation Initiative:

http://www.fda.gov/Radiation-EmittingProducts/RadiationSafety/RadiationDoseReduction/UCM199904

Media Inquiries: Peper Long, 301-796-4671, 240-429-9205, mary.long@fda.hhs.gov,

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

Live Feeds Disclaimer

The live feeds below are provided direct from the source, including public and private sector sources such as the FDA, Medical Product Manufacturing News, BioSpace, and Twitter Feeds.

The information provided from these feeds are not filtered for content by this blog, nor are they considered the opinion of this blog.

MedCity News » North Carolina

FDA's Center for Devices and Radiological Health

Medical Product Manufacturing News

BioSpace.com Featured News and Stories

BioSpace.com Career News

NC Medical - Twitter Search

Biomedical Engineering - Twitter Search

Medical Device - Twitter Search

Pharmaceutical - Twitter Search

Biologics - Twitter Search

FDA Drug Info - Twitter Feed

FDA Recalls - Twitter Feed

FDA Women's Health - Twitter Feed

FasterCures Twitter Feed